价格

iPS-T

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Thiophene compound, liquid-crystalline medium and liquid-crystal display comprising the same
US 11168255 B2申请人: MERCK PATENT GMBH优先权: 2018
CN
EP
US
4 件公开
Gamma delta T cells derived from induced pluripotent stem cells, and production method therefor
US 12576149 B2申请人: UNIV KOBE NAT UNIV CORP优先权: 2021
CN
US
WO
4 件公开
Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
US 12241089 B2申请人: UNIV KYOTO优先权: 2014
CN
US
4 件公开
Method for reconstructing immune function using pluripotent stem cells
US 9206394 B2申请人: NAKAUCHI HIROMITSU优先权: 2012
US
4 件公开
METHOD FOR PRODUCING REGENERATED T CELL VIA IPS CELL
EP 4273234 A1申请人: THYAS CO LTD优先权: 2021
EP
US
WO
3 件公开
USE OF TRIVALENT CHROMIUM IONS AND/OR METAL CHROMIUM IN PREPARATION OF DRUG FOR IMMUNOTHERAPY OF TUMORS
US 20260240903 A1申请人: SHENZHEN LUOHU PEOPLES HOSPITAL优先权: 2023
CN
US
WO
3 件公开
METHOD FOR PRODUCING CYTOTOXIC T CELLS
EP 4803616 A1申请人: TAKEDA PHARMACEUTICAL CO LIMITED优先权: 2023
CN
EP
WO
3 件公开
CYTOTOXIC T CELLS DERIVED FROM HUMAN T CELL-DERIVED IPS CELLS
US 2023071538 A1申请人: JUNTENDO EDUCATIONAL FOUND优先权: 2020
CN
US
2 件公开
CELL BANK COMPOSED OF IPS CELLS FOR INTRODUCING T CELL RECEPTOR GENE
US 20250177524 A1申请人: THYAS CO LTD优先权: 2021
CN
US
2 件公开
GENE-EDITED NATURAL KILLER CELLS
- US 20260250634 A1
  申请人: CRISPR THERAPEUTICS AG优先权: 2022
  US
  WO
  2 件公开
- US 20250241954 A1
  申请人: CRISPR THERAPEUTICS AG优先权: 2025
  US

药物

iPS-T

专利

GENE-EDITED NATURAL KILLER CELLS